ALLMedicine™ Adult T-cell Leukemia/lymphoma Center

Mar 16th, 2023 - T-cell lymphomas are rare and aggressive tumors, and not only basic research but also the establishment of standard therapies and development of novel drugs for these tumors once lagged behind those for B-cell lymphomas. Now, times have changed. R...

Mar 16th, 2023 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Feb 25th, 2023 - Adult T-cell leukemia/lymphoma (ATLL) has aggressive clinical behaviors, and improving its prognosis is a great challenge. A disease progression model from asymptomatic human T-cell leukemia virus type 1 carrier to aggressive-type ATLL has been pr...

Feb 18th, 2023 - Human T-cell leukemia virus type 1 (HTLV-1), also known as human T-lymphotropic virus type 1, causes the aggressive malignancy known as adult T-cell leukemia/lymphoma (ATL) in 5% of infected people, and a chronic progressive inflammatory disease o...

Feb 17th, 2023 - The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment. To identify favorable prognostic patients after intensive chemotherapy, and who t...

Mar 16th, 2023 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Feb 14th, 2023 - BACKGROUND: Cluster of differentiation 25 (CD25) (p55, Tac or interleukin receptor 2 (IL2Ra) is strongly expressed in virtually 100 % of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human T-lymphotropic virus type 1 (HTL...

Feb 2nd, 2023 - This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).

Dec 1st, 2022 - STUDY OBJECTIVES Primary Objective To define the proportion of subjects with CR after 4-6 cycles of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) in the treatment of adult T-cell leukemi...

Nov 21st, 2022 - PRIMARY OBJECTIVE: I. To determine safety, tolerability, and determine the maximum tolerated dose (MTD) of IL-21 expanded, off the shelf, third-party natural killer (NK) cells and mogamulizumab in patients with relapsed/refractory cutaneous T-cell...

Sep 26th, 2022 - The Japan Ministry of Health, Labor and Welfare (MHLW) has approved valemetostat tosilate (Ezharmia; DS-3201b) for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL).1 The regulatory decision was based on r...

Oct 6th, 2021 - Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma....

Feb 17th, 2021 - Questions from the phase 3 ECHELON-2 trial (NCT01777152), which led to the 2018 FDA approval of brentuximab vedotin (Adcetris) plus chemotherapy for patients with CD30-expressing peripheral T-cell lymphoma (PTCL), have given way to additional rese...

Dec 5th, 2020 - Christopher Dittus, DO, MPH I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine—patients in desperate need of medical care and patients with genuinely novel pathology. The dow...

Dec 5th, 2020 - More than half a century has passed since interferons (IFNs) were first discovered. Since then, they have evolved from a cure-all for cancer, as they were initially touted, to a more tempered yet equally vital role in treating a number of differen...